Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A115DF | ISIN: US12637N2045 | Ticker-Symbol: CSJA
Siehe auch CSL LIMITED
Frankfurt
06.06.25 | 08:07
67,00 Euro
-1,47 % -1,00
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
CSL LIMITED ADR Chart 1 Jahr
5-Tage-Chart
CSL LIMITED ADR 5-Tage-Chart

Aktuelle News zur CSL LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCSL LIMITED: Notification of cessation of securities - CSL13
23.05.NICE endorses CSL Vifor's sparsentan for IgA nephropathy in adults19
23.05.NICE relents and backs drug for IgAN from CSL Vifor4
23.05.Vifor International AG (CSL Vifor): England's NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy323First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on...
► Artikel lesen
22.05.Should I buy the dip on CSL shares?5
21.05.CSL Behring's first commercial shows Hizentra erasing germ concerns for primary immunodeficiency patients26
21.05.CSL shares among most expensive on ASX. Is now a good time to buy?3
CSL LIMITED ADR Aktie jetzt für 0€ handeln
21.05.CSL LIMITED: Notification of cessation of securities - CSL1
12.05.Are CSL shares at risk from the Trump tariffs?19
11.05.What did CSL have to say at Macquarie's 2025 conference?3
08.05.CSL LIMITED: Notification of cessation of securities - CSL10
05.05.CSL shares have climbed 10% since 11 April. Is it too late to buy?6
04.05.CSL LIMITED: Shareholder Information Meetings7
29.04.Travere Therapeutics, Inc.: Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy337European Commission converts conditional approval of FILSPARI into standard marketing authorization for the treatment of IgAN EU approval is based on the complete data set from the Phase 3 PROTECT...
► Artikel lesen
29.04.Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy316European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive...
► Artikel lesen
28.04.How Trump's tariffs have created 'upside potential' for CSL shares16
15.04.Is the CSL share price a buy? Here's a top broker's view5
14.04.CSL shares are having a tough time recently. Are they a buy or a sell?8
11.04.As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay63
10.04.CSL LIMITED: Notification of cessation of securities - CSL1
Weiter >>
111 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1